The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.
Jean-Marie Michot, MD
Advertisement
Articles by Jean-Marie Michot, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
3
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5